🏥FDA Seeks Comments for NARMS 2026-2030 Strategic Plan
National Antimicrobial Resistance Monitoring System 2026-2030 Strategic Plan; Request for Comments
Summary
The Food and Drug Administration (FDA, we, or Agency) is soliciting comments from the public regarding the National Antimicrobial Resistance Monitoring System (NARMS) 2026-2030 Strategic Plan. Comments received will help inform the development of a draft 2026-2030 Strategic Plan, to be discussed at a public meeting in spring 2025. Specific questions and information requests are included in this notice to help guide input from interested parties.
Agencies
- Health and Human Services Department
- Food and Drug Administration
Business Impact
$$ - Med
The FDA’s request for comments on the NARMS 2026-2030 Strategic Plan indicates potential regulatory changes affecting antimicrobial monitoring, impacting businesses in the food production and healthcare sectors. Stakeholder input will inform future strategies, which may lead to new compliance requirements for manufacturers and food suppliers related to antimicrobial resistance.